Molbio Diagnostics IPO Sees Subscription Rate of 0.19x, Allotment Scheduled for August 13

The Molbio Diagnostics IPO, which opened for subscription on August 10, 2026, has recorded an overall subscription rate of 0.19x as of the latest update on August 10, 2026, at 11:50 AM. Retail investors have shown a moderate level of interest with bids covering 0.3x of the shares available, while the Non-Institutional Investor (NII) category has seen a lower subscription of 0.15x. Within the NII segment, Big HNIs are lagging with a subscription of just 0.1x, contrasting with Small HNIs, who have a more favorable response at 0.25x subscription. This indicates a mixed sentiment around the IPO in its early days, as it stands currently undersubscribed, which could potentially enhance allotment chances for retail participants.

There has not been any mention of grey market sentiments regarding the Molbio Diagnostics IPO in the provided news. This is an important aspect for investors to consider as grey market trading often reflects the expected listing price and can influence retail investor appetite. The current undersubscription could position the company favorably for additional visibility or promotional efforts leading up to the close of subscription on August 12, 2026, and the subsequent listing date of August 17, 2026.

For Indian investors, the Molbio Diagnostics IPO provides an opportunity to invest in a healthcare technology company at an embryonic stage of its public journey. The undersubscribed nature of the offering may allow retail investors to secure allotments more easily than in oversubscribed IPOs, albeit with the awareness that lower demand could also signal concerns over the company’s market positioning or growth potential. As the subscription window progresses, investors may want to watch how various investor segments adjust their bids and whether any substantial grey market interest emerges that could offer insights into the anticipated listing strategy.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)